AbstractTwenty-five patients with myeloproliferative diseases were treated with pegylated interferon alpha-2b. Prior to therapy, 15/25 patients had a JAK2(V617F) mutation. Eight JAK2-positive patients were on therapy in hematological complete remission at 24 months. Five of eight patients demonstrated a 1.2-3.6 fold reduction in the percentage of JAK2(V617F) cells.
Figures & Tables
Vol. 91 No. 9 (2006): September, 2006 : Clinical Trial, Phase II
Ferrata Storti Foundation, Pavia, Italy
Statistics from Altmetric.com